T. Rowe Price Investment Management
IMCR icon

T. Rowe Price Investment Management’s Immunocore IMCR Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57M Sell
1,891,600
-4,069,627
-68% -$132M 0.04% 329
2025
Q4 		$207M Sell
5,961,227
-1,102,669
-16% -$38.9M 0.13% 165
2025
Q3 		$257M Sell
7,063,896
-3,763
-0.1% -$128K 0.16% 144
2025
Q2 		$222M Buy
7,067,659
+15,841
+0.2% +$492K 0.14% 168
2025
Q1 		$209M Buy
7,051,818
+351,610
+5% +$10.5M 0.14% 166
2024
Q4 		$198M Buy
6,700,208
+200,373
+3% +$6.33M 0.12% 180
2024
Q3 		$202M Buy
6,499,835
+3,507,562
+117% +$128M 0.12% 183
2024
Q2 		$101M Buy
2,992,273
+2,258,662
+308% +$115M 0.06% 279
2024
Q1 		$47.7M Buy
733,611
+359,050
+96% +$24.6M 0.03% 403
2023
Q4 		$25.6M Buy
+374,561
New +$19.5M 0.02% 467

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management's IMCR Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Immunocore (IMCR) stake by 68% in Q1 2026, selling an estimated $132M and leaving 1,891,600 shares worth $57M. The position accounts for 0.04% of the portfolio, ranked #329.

T. Rowe Price Investment Management first reported a position in IMCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $257M in Q3 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • T. Rowe Price Investment Management held 1,891,600 shares of Immunocore worth $57M as of Q1 2026.
  • T. Rowe Price Investment Management sold 4,069,627 Immunocore shares in Q1 2026, an estimated $132M.
  • Immunocore made up 0.04% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #329 holding.
  • T. Rowe Price Investment Management first reported a position in Immunocore in Q4 2023 and has held it in 10 quarters since.
  • T. Rowe Price Investment Management's Immunocore position peaked at $257M in Q3 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.